Baricitinib
Indication
Rheumatoid arthritis (LSCMMG pathway)
MHRA Drug Safety Update, 26 April 2023
Red
Brand:
Olumiant
Nice TA:
466
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
To be used according to the: 'Rheumatoid Arthritis LSCMMG Recommended High-Cost Drugs Pathway'
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: